⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Takeda Pharmaceutical Company Limited and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Takeda is a global, research-and-development-driven biopharmaceutical leader headquartered in Tokyo, Japan. The company focuses on delivering transformative treatments in core therapeutic areas including oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies, and vaccines.
Following its $62 billion acquisition of Shire in 2019, Takeda significantly expanded its footprint in rare genetic disorders and immunology. It operates a robust global R&D network with major hubs in Cambridge (Massachusetts), San Diego (California), and Shonan (Japan), and maintains a presence in over 80 countries.
CLASSIFICATION
SIZE & FINANCIALS
Employees:10000+
Revenue:$20B-$30B
Founded:1781
Ownership:public
Status:operating
STOCK
Exchange:TYO|NYSE
Ticker:4502|TAK
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, Biologics, Plasma-derived therapies, Vaccines
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Various academic and biotech collaborations for R&D
COMPETITION
Position:Leader
Competitors:Pfizer, Novartis, Roche, Merck, AbbVie
LEADERSHIP
Key Executives:
Christophe Weber - CEO and President
LINKS
Website:takeda.xom
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Takeda Pharmaceutical Company Limited. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.